Actively Recruiting
Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
Led by Collegium Medicum w Bydgoszczy · Updated on 2025-11-17
4000
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion. The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available. The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.
CONDITIONS
Official Title
Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All consecutive patients who underwent PCI or coronary angiography during the study period
- Availability of variables required for analysis including serum creatinine measurements before and after the procedure
- Volume of iodine-based contrast media administered between 50 and 500 mL
You will not qualify if you...
- Missing variables required for analysis
- Volume of contrast agent less than 50 mL or greater than 500 mL
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Collegium Medicum w Bydgoszczy
Bydgoszcz, Poland, 85-094
Actively Recruiting
Research Team
P
Piotr Niezgoda, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here